학술논문
First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report.
Document Type
Article
Author
Source
Subject
*THERAPEUTIC use of monoclonal antibodies
*BIOPSY
*CELL receptors
*COMPUTED tomography
*EPIDERMAL growth factor
*LUNG tumors
*MEMBRANE proteins
*METASTASIS
*GENETIC mutation
*TREATMENT effectiveness
EPITHELIAL cell tumors
*
*
*
*
*
*
*
*
*
Language
ISSN
1759-7706
Abstract
A 90‐year‐old female was admitted to our hospital with a history of a dry cough. Chest computed tomography (CT) scan showed a tumor shadow, and CT‐guided lung biopsy revealed squamous cell carcinoma harboring an EGFR mutation. In addition, programmed death‐ligand 1 (PD‐L1) was highly expressed with a tumor proportion score (TPS) of >75%. Pembrolizumab therapy in the first‐line setting was not effective, and the patient died at six months from the first visit. Squamous cell lung cancers (SCLCs) with both EGFR mutation and high expression of PD‐L1 are very rare. [ABSTRACT FROM AUTHOR]